- New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
- Roche’s Vabysmo showed extended durability, continued efficacy and a consistent safety profile in long-term diabetic macular edema (DME) study
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity
- Roche receives CE Mark for its AI-enabled continuous glucose monitoring solution offering critical predictions to people living with diabetes
- Roche to reintroduce Susvimo in the US for people with neovascular age-related macular degeneration (nAMD)
- FDA approves Roche’s Vabysmo prefilled syringe (PFS) for three leading causes of vision loss
- [Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase II/III SKYSCRAPER-06 study in metastatic non-squamous non-small cell lung cancer
- Roche’s Vabysmo gets CHMP recommendation for third indication retinal vein occlusion (RVO)
- CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
- Roche expands access to cervical cancer screening tools with two new WHO prequalification designations, including HPV self-collection
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 246.25 |
Low | 246.25 |
Bid | -- |
Offer | -- |
Previous close | 246.25 |
Average volume | -- |
---|---|
Shares outstanding | 809.25m |
Free float | 731.55m |
P/E (TTM) | 19.47 |
Market cap | 227.84bn CHF |
EPS (TTM) | 14.30 CHF |
Annual div (ADY) | 9.98 EUR |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Mar 14 2024 |
Div pay-date | Mar 18 2024 |
Data delayed at least 15 minutes, as of Jun 28 2019 07:00 BST.
More ▼